RDY vs UTHR: Dr. Reddy’s Laboratories Ltd ADR and United Therapeutics compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- United Therapeutics is the larger company, worth $22.8B, about 2.1 times Dr. Reddy’s Laboratories Ltd ADR.
- Dr. Reddy’s Laboratories Ltd ADR grew revenue faster over the last year (+16.6% vs -1.9%).
- United Therapeutics keeps more of each dollar of revenue as operating profit (44.4% vs 22.1%).
- On earnings, United Therapeutics is the cheaper stock (19.8x vs 25.2x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | RDY | UTHR |
|---|---|---|
| Market cap | $10.9B | $22.8B |
| Share price | $12.48 | $549.16 |
| Revenue (last fiscal year) | $325.5B | $3.2B |
| Free cash flow (last fiscal year) | $12.0B | $1.0B |
| Revenue growth, last year | +16.6% | -1.9% |
| Revenue growth per year, last 5 fiscal years | +14.5% | +17.2% |
| Operating margin | 22.1% | 44.4% |
| Net margin | 17.4% | 41.6% |
| Return on equity | 17.0% | 20.5% |
| P/E (trailing) | 25.2x | 19.8x |
| Price / free cash flow | 0.34x | 21.9x |
| EV / EBITDA | 13.9x | 11.7x |
| FCF growth the price implies | — | 6.2% |
| Dividend yield | 0.63% | — |
| Debt / equity | 0.47x | 0.13x |
| Fundamental grade | B | B |
| Superinvestors holding it | 0 | 0 |
| Insider purchases, last 12 months | 0 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Dr. Reddy’s Laboratories Ltd ADR
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $189.7B | $23.1B | 12.8% |
| 2022 | $214.4B | $9.1B | 13.7% |
| 2023 | $245.9B | $40.0B | 23.2% |
| 2024 | $279.2B | $18.0B | 24.3% |
| 2025 | $325.5B | $12.0B | 22.1% |
United Therapeutics
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $1.7B | $477M | 33.0% |
| 2022 | $1.9B | $664M | 50.6% |
| 2023 | $2.3B | $748M | 50.9% |
| 2024 | $2.9B | $1.1B | 47.9% |
| 2025 | $3.2B | $1.0B | 46.9% |
Where the revenue comes from
Dr. Reddy’s Laboratories Ltd ADR · by segments, 2026
Global Generics$299.0B89%
Pharmaceutical Services and Active Ingredients$34.8B10%
Other segment$2.1B1%
United Therapeutics · by products, 2025
Tyvaso DPI$1.3B41%
Nebulized Tyvaso$586M18%
Remodulin$527M17%
Orenitram$497M16%
Unituxin$227M7%
Adcirca$30M1%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open RDY in InvestinglyQuestions
Which is bigger, Dr. Reddy’s Laboratories Ltd ADR or United Therapeutics?
United Therapeutics (UTHR), at $22.8B against $10.9B.
Is RDY or UTHR cheaper?
By trailing P/E, United Therapeutics (19.8x) is cheaper than Dr. Reddy’s Laboratories Ltd ADR (25.2x). A lower multiple can also mean the market expects less growth.
Which grows faster, RDY or UTHR?
Dr. Reddy’s Laboratories Ltd ADR: revenue grew +16.6% over the last year, against -1.9%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.